A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Background of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR)

Trial Profile

A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Are on a Stable Background of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Apr 2018

At a glance

  • Drugs Upadacitinib (Primary) ; Adalimumab
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms SELECT-COMPARE
  • Sponsors AbbVie
  • Most Recent Events

    • 09 Apr 2018 According to the AbbVie media release, additional data from this study will be presented at a future medical meeting and published in a peer-reviewed publication.
    • 09 Apr 2018 Primary endpoint proportion of subjects achieving Clinical remission (CR) based on Disease Activity 28 (DAS28) C-Reactive Protein (CRP) has been met, according to the AbbVie media release.
    • 09 Apr 2018 Primary endpoint proportion of participants achieving American College of Rheumatology (ACR) 20 Response) has been met, according to the AbbVie media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top